Researchers develop blood test for stress

Published Date: 08 Mar 2023

Researchers at Indiana University School of Medicine have developed a blood test for stress. This test assesses a person's risk of stress,...

Read Full News

Latest News

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

AI Scribes Reduce Physician Burnout Within 30 Days, With Lee Schwamm, MD Lee Schwamm, MD

Physicians experience significant challenges with increasing administrative burdens impacting patient care. Study shows AI scribes can help reduce burnout.

Adding CBT to Quetiapine Significantly Reduces Suicide Risk in Mood Disorders

Adding CBT to Quetiapine Significantly Reduces Suicide Risk in Mood Disorders

FDA Approves ProlivRx, First At-Home Neuromodulation Device for MDD

FDA Approves ProlivRx, First At-Home Neuromodulation Device for MDD

Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies

Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies

Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms

Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms

Todays Updates

The Skin–Brain Axis: Emerging Evidence Transforming Dermatologic Care Lisa A. Swanson, MD, Enzo Berardesca, MD, Mohammad Jafferany, MD

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

Phase 2 Study of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy: The REVISE Trial Isabella Ciccone, MPH

The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.

FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials Noah Stansfield

Intellia’s trial for nex-z in ATTR-CM remains under clinical hold.

Navigating Opportunities and Obstacles in Gastroparesis, With Ronen Arai, MD Ronen Arai, MD

Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.

IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis

IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis

Todays Updates

The Skin–Brain Axis: Emerging Evidence Transforming Dermatologic Care Lisa A. Swanson, MD, Enzo Berardesca, MD, Mohammad Jafferany, MD

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

Phase 2 Study of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy: The REVISE Trial Isabella Ciccone, MPH

The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.

FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials Noah Stansfield

Intellia’s trial for nex-z in ATTR-CM remains under clinical hold.

Navigating Opportunities and Obstacles in Gastroparesis, With Ronen Arai, MD Ronen Arai, MD

Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.

IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis

IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis

Latest News

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

Physicians experience significant challenges with increasing administrative burdens impacting patient care. Study shows AI scribes can help reduce burnout.

Adding CBT to Quetiapine Significantly Reduces Suicide Risk in Mood Disorders

FDA Approves ProlivRx, First At-Home Neuromodulation Device for MDD

Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies

Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms

News All Time

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Single Dose of MM120 (LSD) Shows Lasting Anxiety Reduction in GAD: Phase 2b Results Chelsie Derman

A phase 2b trial finds a single 100 μg dose of MM120 reduced GAD symptoms with benefits lasting 12 weeks, highlighting the promise of psychedelic therapy.

FDA Releases CRL Detailing Safety Concerns for MDMA-Assisted Therapy in PTSD Chelsie Derman

MDMA’s CRL, now available to the public, cites gaps in safety data, selection bias, and limited durability.

Prenatal Opioid Pain Medications Likely Not Linked to Autism or ADHD Risk Chelsie Derman

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

FDA Initiates Acetaminophen Label Change, Leucovorin Approval for Cerebral Folate Deficiency Abigail Brooks, MA

The Agency initiated an acetaminophen label change to reflect evidence of potential harms in pregnant women and an approval of leucovorin for CFD.

Atopic Eczema Linked to Suicidal Ideation in Global Study of 30,000 Adults Chelsie Derman

EADV 2025 findings show patients with atopic eczema face greater risks of depression, anxiety, sleep disorders, and stigmatization.

Daily Ammoxetine at 40, 60 mg Outperforms Placebo for MDD in Phase 2 Trial Chelsie Derman

A phase 2 trial demonstrated the effectiveness, safety, and tolerability of ammoxetine (40 and 60 mg) in patients with major depressive disorder.

APhA, Coalition of Autism Scientists Cite Insufficient Data to Support Acetaminophen, Autism Link Abigail Brooks, MA

Both organizations defend the use of Tylenol during pregnancy, citing “rigorous” and “reputable” research suggesting it does not cause autism in children.

5 Psychiatry Headlines You Missed in September 2025 Chelsie Derman

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

Q3 2025 Recap: Psychiatry News and Updates Chelsie Derman

Explore the latest advancements in psychiatry, including FDA updates, emerging therapies, and promising clinical trial results for mental health treatments.

I Tried to End My Life 3 Times: Today, I Help Others Fight for Theirs Diana Guzman, LMHC

Therapist Diana Guzman, LMHC, writes about attempting suicide despite counseling patients battling with suicidal ideation.

Digital Therapeutic Reduces Negative Symptoms of Schizophrenia in Phase 3 Trial Chelsie Derman

A new digital therapeutic, CT-155, shows promise in reducing negative symptoms of schizophrenia.

FDA Approves Risperidone Extended-Release Injectable for Bipolar I Disorder Chelsie Derman

FDA approves UZEDY, a long-acting risperidone injection, for adults with bipolar I disorder.

Soft Drinks Linked to Depression Through Gut Microbiota Alterations Chelsie Derman

New research links soft drink consumption to depression, revealing gut microbiota changes as a potential mediator, particularly in women.

Recommended News For You

Clinical trial: Patients with locally advanced, muscle-invasive bladder cancer do not benefit from extended lymph node removal.

Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma

The Benefits of Exercise for Substance Use Disorders.

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs

Launch of the hereditary cancer clinic for precision oncology at Kokilaben Hospital.

Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics

Report: Breast cancer mortality continues three decade decline, but steeper increases in incidence for some women

Recommended Articles For You

Targeting Oncology: Expanding Combinatorial Strategies by 2025 

Exploring the Causes and Treatments of Cysts: A Comprehensive Guide 

CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Comprehensive Review 

Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

One CAR T-Cell Therapy for Multiple Myeloma Tops Another in Propensity Matched Study

2.

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

3.

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

4.

MRI-guided radiation therapy improves quality of life with fewer side effects in patients with localized cancer. JAMA

5.

According to a study, patients with ovarian cancer who undergo aggressive surgery have a 70% lower chance of dying.

1.

Protein S-Palmitoylation in Cancer: A Novel Target in Immunotherapy & Treatment

2.

The Power of Salt Tablets: Unlocking Health Benefits Beyond Sodium

3.

Breast Cancer Secrets: AI-Powered Precision Medicine

4.

What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder

5.

Unlocking the Mystery of Hemoglobin C Trait: A Closer Look at a Rare Blood Disorder

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

3.

Thromboprophylaxis In Medical Settings- An Update

4.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

5.

Efficient Management of First line ALK-rearranged NSCLC - Part VIII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot